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Oral lichen planus (OLP) is a chronic oral inﬂammatory disease of unknown etiology. According to reports, 1-2% of OLP patients
develop oral squamous cell carcinoma (OSCC) in the long run. While World Health Organization (WHO) classiﬁes OLP as “a
potentially malignant disorder,” it is still a matter of debate which mechanisms drive OLP to such a condition. The current
hypothesis connecting OLP and OSCC is that chronic inﬂammation results in crucial DNA damage which over time results in
cancer development. Initial studies investigating the OLP and OSCC link were mainly retrospective clinical studies. Over the past
years,severalamountofinformationhasaccumulated,mainlyfrommolecularstudiesontheOLPmalignantpotential.Thisarticle
is a critical review of whether OLP has a malignant potential and, therefore, represents a model of preneoplastic inﬂammation.
1.Introduction
Oral lichen planus (OLP) is a chronic inﬂammatory oral
condition of unknown aetiology characterized by T-cell-
mediated chronic immune response and abnormal epithelial
keratinization cycle [1]. The OLP lesions may coexist with
cutaneous and genital lesions, or may be the only disease
manifestations [2]. The epidemiology of OLP is not easy to
calculate with reported incidence ranging between 1-2% of
the general population. Recent meta-analysis calculated a
1.27% incidence in the general population [3]. The OLP
lesions are consistently more persistent than the dermal
lesions and have been reported to carry a risk of malignant
transformation to oral squamous cell carcinoma (OSCC) of
1-2% (reported range of malignant transformation 0–
12.5%) [4]. Clinically, OLP appears more commonly with
the classic reticular form, which results from coalition of
papules and may be asymptomatic or may cause mild dis-
comfort. Erythema, erosions, and ulceration could also
appear and these are the most painful OLP manifestations,
while if the lesions become chronic they may become
hyperplastic or atrophic [4]. The lesions of OLP tend to
present symmetrically and bilaterally especially in the buccal
mucosa [5]. Histological examination of OLP reveals, dense
inﬂammatory inﬁltrate in the upper lamina propria, mainly
consisting of T-cells, liquefaction degeneration of basal
k eratinocyt esandbasalmembraneh yperk erat osisoratr o ph y
of the keratin layer [6, 7]. The pathogenesis of OLP is very
complex and involves possible antigen presentation by the
oral keratinocytes that could be either of an exogenous or an
endogenousorigin[8–10].Thisantigenictriggerisaccompa-
nied by a mixed inﬂammatory response comprising mainly
T-cells, macrophages, and mast cells, as well as the associated
cytokines and cytotoxic molecules [4, 8–10]. Oﬃcially, the
World Health Organisation (WHO) classiﬁes OLP as a
“potentially malignant disorder” with unspeciﬁed malignant
transformation risk and suggests that OLP patients should
be under close monitoring [11]. The possible premalignant2 Journal of Biomedicine and Biotechnology
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Figure 1: The current hypothesis on the development of dysplasia and cancer in OLP suggests that changes in epithelial cells (keratinocytes)
is a result of detuning in cellular replication, DNA damage and disorganization of epithelial integrity, secondary to oxidative stress, cytokine,
and transcription factor signals originating from the inﬂammatory inﬁltrate.
nature of OLP has been the subject of numerous studies and
great controversies [4, 5]. Treatment of OLP is remarkably
unsatisfying; topical steroids are the ﬁrst treatment choice
and systemic corticosteroids and immunosuppressants are
the second line agents, but none of them can result in signif-
icant long-term disease control [12]. Severe erosive disease
leaving mucosal atrophy and requiring systemic treatment
is reported to carry the highest risk of malignant transfor-
mation [13]. There is no deﬁnite malignant transformation
mechanism identiﬁed in OLP. The current hypothesis is
that chronic stimulation from the inﬂammatory and stromal
cells is providing the signals that are causing epithelial cells
to derange their growth control and in cooperation with
oxidative stress, from oxidative and nitrative products, it
provokes DNA damage resulting in neoplastic changes [4,
14–17]( Figure 1). Recently, OLP has been proposed to be an
ideal model of inﬂammation induced cancer [18].
The advances in molecular information on this patho-
logic condition have shed new light on the complex patho-
genesis of OSCC arising in OLP and this article is an attempt
to review the currently available data.
2. CellCycleControl inOral Lichen Planus
Apoptosis of basal keratinocytes, caused by the activity of
cytotoxic T-cells, could be a possible explanation for one of
the histopathologic hallmarks of OLP that is the vacuolar
degeneration of basal membrane [8]. This is also supported
by several molecular studies demonstrating the presence of
apoptotic signals in OLP [10, 19, 20].
Nevertheless, if apoptosis was the main cellular event,
then all cases of untreated OLP would end up with severe
and extensive oral mucosa erosions [21]. However, this is not
the case in the majority of OLP, as the most common clinical
form of OLP is reticular lichen planus, while the erosive
forms usually are limited in one or two oral sites [4, 5].
Therefore, a counterbalancing mechanism is expected as a
response from the oral epithelium to maintain its integrity.
In fact, several molecular studies indicated evidence of
increased cellular turnover rate, in the form of increased cel-
lular proliferation, in epithelial cells of oral lichen planus
[21–24]. In addition, other authors have demonstrated mix-
ed patterns of both apoptosis and increased cellular prolifer-
ation occurring simultaneously [25–27].
Even more, Gonz´ alezetal.suggestedthatpossiblyepithe-
lial cells in OLP respond to the inﬂammatory chronic attack
by exhibiting a senescent phenotype instead of apoptosis.
This hypothesis was based on the observed positive p21WAF1
expression in OLP, which is indicative of cell cycle arrest and
possibly of senescence [28].
Cell cycle arrest helps in maintaining tissue integrity and
facilitating DNA repair mechanisms, but at the same time
entry into senescence could favor malignant transformation
[29–31]. As the authors note too, positive p21WAF1 is only
indicative of senescence, in contrast to the most established
marker of senescence which is SA-beta gal staining [28].
Nevertheless, given that this staining method is not suitable
for paraﬃne m b e d d e dt i s s u e s ,[ 32] which is the most widely
available material for OLP studies, data after applying this
method are lacking.
In a similar hypothetical model, Poomsawat et al., con-
sidered their observations of increased p16INK4A and cdk4
expressioninOLPasevidenceofaprecancerousOLPprocess
[33]. In a contradictory study, Montebugnoli et al. did
not ﬁnd signiﬁcant diﬀerences in p16INK4A expression in
OLP and nonspeciﬁc oral inﬂammation and interpreted the
p16INK4A expression only as a sign of inﬂammation [34].
3. The Role of p53 inOLP
Inactivation of p53 is a frequent phenomenon in OSCC.
This is caused by mutations, presence of HPV virus and
other molecular alteration occurring in the p53 pathway
[35]. The studies investigating the expression of p53 in OLPJournal of Biomedicine and Biotechnology 3
have been recently reviewed by Ebrahimi et al. [36]. In their
vast majority, they included immunohistochemistry-based
reports and their results varied signiﬁcantly, with reported
expression percentages ranging from 0–100%. Nevertheless,
most of them found signiﬁcantly higher expression in OLP
than in normal oral mucosa [36]. As p53 expression has been
identiﬁed as a response to DNA damage, [37] the identiﬁ-
cation of p53 in OLP tissue is interpreted as an indication
of precancerous potential by some researchers [24, 38]. In
support to this concept, Chaiyarit et al. showed an i-NOS-
dependentDNAdamageandp53elevatedexpressioninOLP
patients [39]. Another concept is that the high expression
of p53 in OLP is a result of the higher cellular proliferation
[22, 40]. To prove that p53 expression in OLP is not just
a result of the inﬂammatory process, Safadi et al. [38]
compared the immunohistochemical expression of p53 and
of its downstream eﬀector p21WAF1 between OLP and other
inﬂammatory oral conditions and found signiﬁcantly higher
expressioninOLP[38].Whatisstillunclearistheunderlying
mechanism that drives p53 expression in a signiﬁcant
percentage of OLP cases, but as p53 expression in OLP is
comparable to that observed in dysplastic oral lesions, it is
considered as a sign of malignant potential [36].
At this point, it is tempting to speculate that OLP as
an inﬂammatory condition, along with the accompanying
oxidative stress, probably induces a genotoxic stress. In addi-
tion, the high proliferation rates reported for the oral epi-
thelium turnover in OLP may also create a replication stress.
Such conditions should activate the DNA damage response
(DDR) checkpoint [41, 42]. In turn, this pathway should
elicit the p53-mediated antitumor barriers of apoptosis and
senescence. Continuous activation of this checkpoint will
eventually surpass the cell repair capacity predicting the
emergence of genomic instability and ﬁnally selective p53
inactivation. Consecutively, this would result in the progres-
sion to malignancy. Nevertheless, this scenario requires ex-
perimental validation, despite the presence of experimental
evidence compatible with it.
4. Chromosomal InstabilityinOLP
To verify the OLP malignant potential hypothesis, genetic
alterations observed in epithelial cancers have also been
studied in OLP. In 1997, Zhang et al. used microsatellite
analysis to investigate loss of heterozygosity (LOH) at loci
3p, 9p, and 17p, which is frequently observed in oral cancers
[43]. Despite they detected LOH, their results showed no
diﬀerent frequencies from the reactive irritation (benign
inﬂammation). Nevertheless, while this result did not sup-
portOLPasalesionatriskformalignanttransformation,the
authors could not exclude that OLP may undergo malignant
transformationthroughothergeneticpathways[43].Follow-
ing these results, the same authors performed the same loci
analysis in dysplastic lesions in OLP patients and their results
showed comparable rates of allelic loss with those observed
in epithelial dysplasia even for cases of mild dysplasia [44].
From this ﬁnding they concluded that dysplasia observed
in OLP cases is possibly an independent risk factor for
malignant transformation and underlined that very diligent
clinical and pathologic approach should be applied in the
case of OLP biopsies [44]. Similar results and conclusions
especially for LOH in chromosome 9 in OLP-associated
dysplasia were reported by Kim et al. with the use of
chromosomal in situ hybridization [45]. On the other hand,
in a more recent study using laser capture microdissection
and microsatellite analysis to identify LOH, the results were
similar in benign lesions and OLP samples weakening the
concept of malignant OLP potential, but these authors also
emphasize on careful histopathologic examination of OLP
samples [46]. Of note, all data available from LOH analyses
are conﬁned only to chromosomes 3, 9, and 17 [43–46]. To
the best of our knowledge, genome-wide analyses in large
cohorts of OLP are still missing.
Changes in DNA ploidy are also an indication of
malignancy. DNA ploidy studies in OLP have demonstrated
that some atrophic lesions may be found aneuploid, but the
results are not indicative of a potentially malignant process
[47–49]. Abnormal karyotypes and chromosomal alterations
associated with p53 expression have also been detected in
OLP, but the data are small to allow safe conclusions [50].
5.MatrixMetalloproteinases(MMPs) andOLP
Sutinen et al. were among the ﬁrst to investigate the
expression of MMPs and their inhibitors TIMPs in clinical
sampleswithOSCC,OLP,dysplasia,lymphnode,metastases,
a n dn o r m a lo r a lm u c o s a[ 51]. Though their ﬁndings showed
signiﬁcantly higher expression in OSCC in comparison to
the other lesions, they ﬁrst noted a weak MMP 1 and 2
expression in some OLP cases [51]. Subsequently, Zhou et al.
reported increased expression of MMP 1–3 in the epithelial
OLP cells and MMP-9 in the OLP inﬂammatory inﬁltrating
cells, but not the TIMPs, and suggested a role of MMPs in
the basement membrane disruption, which possibly enables
intraepithelial inﬂammatory cell migration [52].
The role of MMPs in OLP was initially associated with
apoptosis of epithelial cells and the level of inﬂammation
[53]. Transforming growth factor beta (TGF-β) and the
bone morphogenic protein-4 (BPM-4) were suggested as
promotingsignalsfortheupregulationoftheMMPs[53,54].
Chen et al., studied MMPs, TIMPs and TGF-b in OSCC that
developed from previous OLP and found constant expres-
sion with levels comparable to those detected in atrophic
OLP, which is the form of OLP reported to have the higher
malignant potential [55]. They concluded that their ﬁndings
are suggestive of the role MMPs have in the malignant trans-
formation in OLP [55]. More recently, Tsai et al. detected
elevated MMP-2 levels both in situ, and in peripheral blood
of the same patients, interpreting their ﬁndings as indices of
systemic inﬂammation, in OLP [56].
6.The Role of NF-KappaB andAssociated
Cytokines(IL-1α,IL -6 ,IL -8 ,T N F)
The transcription factor Nuclear Factor kappa betta (NF-
kappaB) has been described as a major molecule associating
chronic inﬂammation and cancer mainly by inhibiting4 Journal of Biomedicine and Biotechnology
apoptosis, promoting cellular proliferation and favoring
metastatic phenotypes [57]. The expression of NF-kappaB
has been reported higher in OLP than in cutaneous lichen
planus (CLP), a fact that is considered consistent with
the more persistent inﬂammation observed in OLP in
comparison to CLP [58]. In support to the above, the levels
of NF-kappaB associated cytokines (IL-1α, IL-6, IL-8, TNF)
have been found increased in whole unstimulated saliva
and other oral ﬂuids of OLP patients [59–61] and also in
OSCC patients [60]. These observations are suggestive for
a role of NF-kappaB and of the associated cytokines in
the inﬂammatory process of OLP and possibly also in the
malignant transformation of OLP [59–61].
TNF is one of the most studied cytokines linking chronic
inﬂammation and cancer by inducing neoplastic cellular
phenotypes, and angiogenesis [62]. TNF involvement in the
pathogenesis of OLP has been proposed for more than 15
years ago [63]. Since then, several studies demonstrated
ﬁndings supporting the TNF involvement in OLP pathogen-
esis. These include TNF genetic polymorphisms with OLP
susceptibility, [64–67] elevated serum and saliva TNF levels
in patients with OLP, [68–71]a n din situ detection of TNF
in OLP epithelium [72, 73]. Its role is also supported by the
favorable results of anti-TNF agents in patients with OLP
[74, 75].
IL-6 expression in serum and saliva of OLP patients
[76] is considered indicative of a Th2 cellular involvement
in OLP, [77, 78] a fact that was underestimated initially
in the pathogenesis of OLP [8]. Similarly, IL-6 has been
associated with promoting colon cancer development in
inﬂammatoryboweldiseases[79,80].Furthermore,IL-6and
IL-8 expression is associated with the senescence phenotype
and has been suggested that they promote senescence-related
growth arrest [81].
7.HepatitisCVirus(HCV)Infectionand
OLP MalignantPotential
HCVinfectionhasbeenassociatedwithOLPpathogenesisin
certain ethnic populations, especially in the Mediterranean
area[82].HCVinfectionisawell-documentedriskfactorfor
hepatocellular carcinoma development [83]. Also, chronic
HCV infection has been implicated with other malignancies
like cholangiocarcinoma and lymphomas [84]. The patho-
genetic mechanisms that connect OLP and HCV were based
on the ﬁndings that circulating antibodies against the oral
epithelium were identiﬁed in OLP patients with HCV infec-
tion, [85] and that OLP mediating cytokines are triggered
by HCV infection [86]. A study in Japanese OLP patients
identiﬁed HCV RNA in oral lesions and serum from OLP
and OSCC patients and concluded that it may be involved in
the pathogenesis of OSCC [87]. In contrast, in a study of oral
epithelial dysplasia and HCV infection in British population,
no such association was observed [88]. The association
of HCV infection and OLP development in certain ethnic
groups may be related to HLA subclasses presence, and
though weak, some evidence exists to correlate these diseases
suggesting further investigation [89]. Nevertheless, up to
now no strong evidence exists so far to indicate a possible
strong association of HCV infection with OLP progression
to OSCC.
8. SimilaritiesbetweenInﬂammatory
BowelDiseases(IBD)AssociatedColorectal
CarcinomasandOLP AssociatedOSCC
Inﬂammatory bowel diseases, ulcerative colitis (UC), and
Crohn’s disease (CD) are complicated with colorectal carci-
nomasinapercentagerateof7–14%forUCina25yeartime
frame,anda2.9%cumulativeriskforCDin10years[90,91].
Patients who develop colorectal carcinomas in IBD
may present with multiple sites of cancer and areas of
dysplasia in the same way that patients with OLP-associated
OSCC may develop new primary tumors and dysplastic
lesions in multiple oral sites [92–95]. T-cells and apoptotic
mechanisms have an important role, both in OLP and IBD
pathogenesis [96, 97].
Recently, the role of the neuronal axon guidance
molecule netrin-1 and its receptors (DCC, UNC5H) have
been discovered to play a pivotal role in progression of IBD
tocolonadenocarcinoma,[98,99]anditsexpressionisprob-
ably upregulated through NF-kappaB [100]. This molecule
has not been investigated in OLP and could constitute a
possible link between chronic OLP inﬂammation and cancer
progression, a hypothesis that we currently investigate.
It is possible that both IBD and OLP, as chronic inﬂam-
matory conditions, provide the basis for the establishment of
early preneoplastic lesions. These in turn, under the appro-
priate conditions, may further develop by progressing to
malignant stages. The fact that, in contrast to IBD, OLP
has less percentage of malignant potential is not against this
model as IBD is common in younger adults while OLP is a
disease mainly of post menopausal women. Thus, the time
frame for malignant development is wider in IBD in contrast
to OLP.
9.FutureProspects
Itisclearthatmostofthestudiessofarhaveshownindicative
results of a precancerous OLP nature. Studies that will
include investigation of other unexplored pathways, like the
DDR one, and in larger OLP cohorts, especially including
all the spectrum of lesions up to full-blown cancer from
the same patient, are a prerequisite. A series of evidence
like the oxidative stress due to chronic inﬂammation, the
potential replication stress as exempliﬁed by the observed
high cellular proliferation, the increased p53 expression, and
the genomic instability in OLP are suggesting that DNA
damage is taking place in OLP. The hypothesis that could ﬁt
in OLP carcinogenesis, based on the available data, is that
p53 upregulation in response to continuous oxidative and
replicative DNA damage, protects the OLP-aﬀected cells
from a malignant potential through activation of the cell
cycle arrest, apoptosis and/or senescence. Nevertheless,
sustained DDR activation will eventually overwhelm the
cellular repair capacity. When this repair mechanism exceedsJournal of Biomedicine and Biotechnology 5
its potential, genomic instability will gradually accumulate,
leading eventually to mutation ﬁxation in critical genes. As
a result the antitumor barriers will gradually diminish and
dysplastic changes as well as further ones may occur.
There are still other important questions to consider:
Which is/are the main signals that could promote toward
cancer? What kind of treatment modalities should be
applied?Couldnewtreatmentwithnewbiologicagents(e.g.,
anti-TNF, anti-IL6 receptors) alter the cancer risk in OLP
patients? The development of accurate OLP animal models,
which currently lack, may also prove to be important tools in
the molecular deciphering of both OLP and its progression
to cancer. More research is required to acquire a full view of
the precancerous nature of OLP and to be able to determine
subclasses of OLP patients at increased risk of malignant
transformation.
10. Conclusion
All the ﬁndings so far are indicative that the OLP is a
preneoplasticinﬂammatorymodel.ThefactthatOLPlesions
are found in an open cavity, such as the mouth, that is, acces-
sible to regular monitoring and biopsy, is feasible without
complications and high cost, render OLP an ideal disease
to study the relationship between chronic inﬂammation and
cancer. The focus should be on ﬁnding markers that delimit
the patients at risk of OSCC progression.
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